product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human NKG2D Fc Chimera Protein, CF
catalog :
1299-NK-050
quantity :
50 ug
price :
423 USD
more info or order :
R&D Systems product webpage
citations: 29
Reference
Kaidun P, Holzmayer S, Greiner S, Seller A, Tegeler C, Hagelstein I, et al. Targeting NKG2DL with Bispecific NKG2D-CD16 and NKG2D-CD3 Fusion Proteins on Triple-Negative Breast Cancer. Int J Mol Sci. 2023;24: pubmed publisher
Badrinath S, Dellacherie M, Li A, Zheng S, Zhang X, Sobral M, et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature. 2022;606:992-998 pubmed publisher
Joung J, Kirchgatterer P, Singh A, Cho J, Nety S, Larson R, et al. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nat Commun. 2022;13:1606 pubmed publisher
Ponath V, Frech M, Bittermann M, Al Khayer R, Neubauer A, Brendel C, et al. The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC. Cancers (Basel). 2020;12: pubmed publisher
Muñoz D, Yannone S, Daemen A, Sun Y, Vakar Lopez F, Kawahara M, et al. Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. JCI Insight. 2019;5: pubmed publisher
Han Y, Xie W, Song D, Powell D. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 2018;11:92 pubmed publisher
Prévost J, Richard J, Medjahed H, Alexander A, Jones J, Kappes J, et al. Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. J Virol. 2018;92: pubmed publisher
Liu J, Wang L, Wang Y, Zhang W, Cao Y. Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion. PLoS ONE. 2017;12:e0175704 pubmed publisher
Eggink L, Spyroulias G, Jones N, Hanson C, Hoober J. A Peptide Mimetic of 5-Acetylneuraminic Acid-Galactose Binds with High Avidity to Siglecs and NKG2D. PLoS ONE. 2015;10:e0130532 pubmed publisher
Kruse V, Hamann C, Monecke S, Cyganek L, Elsner L, Hübscher D, et al. Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1. PLoS ONE. 2015;10:e0125544 pubmed publisher
Cho H, Chung J, Kim S, Braunschweig T, Kang T, Kim J, et al. MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer. 2014;14:957 pubmed publisher
Mou X, Zhou Y, Jiang P, Zhou T, Jiang Q, Xu C, et al. The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients. Sci Rep. 2014;4:6138 pubmed publisher
Uhlenbrock F, Hagemann Jensen M, Kehlet S, Andresen L, Pastorekova S, Skov S. The NKG2D ligand ULBP2 is specifically regulated through an invariant chain-dependent endosomal pathway. J Immunol. 2014;193:1654-65 pubmed publisher
Mellergaard M, Skovbakke S, Schneider C, Lauridsen F, Andresen L, Jensen H, et al. N-glycosylation of asparagine 8 regulates surface expression of major histocompatibility complex class I chain-related protein A (MICA) alleles dependent on threonine 24. J Biol Chem. 2014;289:20078-91 pubmed publisher
Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose John S, Moldenhauer G, et al. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer Res. 2014;74:3429-40 pubmed publisher
Nakata J, Nakano K, Okumura A, Mizutani Y, Kinoshita H, Iwai M, et al. In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity. Leukemia. 2014;28:1316-25 pubmed publisher
Rothe A, Jachimowicz R, Borchmann S, Madlener M, Keßler J, Reiners K, et al. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Cancer. 2014;134:2829-40 pubmed publisher
Leung W, Vong Q, Lin W, Janke L, Chen T, Leung W. Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXR? activation. J Exp Med. 2013;210:2675-92 pubmed publisher
Siewiera J, El Costa H, Tabiasco J, Berrebi A, Cartron G, Le Bouteiller P, et al. Human cytomegalovirus infection elicits new decidual natural killer cell effector functions. PLoS Pathog. 2013;9:e1003257 pubmed publisher
Reiners K, Kessler J, Sauer M, Rothe A, Hansen H, Reusch U, et al. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther. 2013;21:895-903 pubmed publisher
Bellucci R, Nguyen H, Martin A, Heinrichs S, Schinzel A, Hahn W, et al. Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest. 2012;122:2369-83 pubmed publisher
Inagaki A, Ishida T, Yano H, Ishii T, Kusumoto S, Ito A, et al. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Int J Cancer. 2009;125:212-21 pubmed publisher
Kwong K, Baskar S, Zhang H, Mackall C, Rader C. Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. J Mol Biol. 2008;384:1143-56 pubmed publisher
El Sherbiny Y, Meade J, Holmes T, McGonagle D, Mackie S, Morgan A, et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007;67:8444-9 pubmed
Banerjee P, Feuer G, Barker E. Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the. J Virol. 2007;81:9707-17 pubmed
Ward J, Bonaparte M, Sacks J, Guterman J, Fogli M, Mavilio D, et al. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood. 2007;110:1207-14 pubmed
Skov S, Pedersen M, Andresen L, Straten P, Woetmann A, Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005;65:11136-45 pubmed
Von Strandmann E, Hansen H, Reiners K, Schnell R, Borchmann P, Merkert S, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood. 2006;107:1955-62 pubmed
Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner E, et al. BCR/ABL promotes dendritic cell-mediated natural killer cell activation. Cancer Res. 2005;65:6409-17 pubmed
product information
brand :
R&D Systems, a Bio-Techne Brand
catalog number base :
1299-NK
SKU :
1299-NK-050
product name :
Recombinant Human NKG2D Fc Chimera Protein, CF
Description :
The Recombinant Human NKG2D Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human NKG2D Fc Chimera Protein, CF has been validated for the following applications: Binding Activity.
target :
NKG2D/CD314
category :
Proteins and Enzymes
unit size :
50 ug
buffer :
Lyophilized from a 0.2 µm filtered solution in PBS.
conjugate :
Unconjugated
purity :
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
species :
Human
observed molecular weight :
44-63 kDa, reducing conditions
theoretical molecular weight :
43 kDa (monomer)
gene symbol :
KLRK1
details of functionality :
Measured by its ability to bind its ligand, rhMICA/Fc Chimera in a functional ELISA.
endotoxin note :
<0.10 EU per 1 µg of the protein by the LAL method.
accessionNumbers :
P26718
applications :
Binding Activity
source :
NS0-derived Recombinant Human NKG2D Fc Chimera Protein
USD :
423 USD
alt names :
CD314, CD314 antigen, D12S2489E, FLJ17759, FLJ75772, Killer cell lectin-like receptor subfamily K member 1, killer cell lectin-like receptor subfamily K, member 1, KLR, KLRK1, NK cell receptor D, NKG2-D, NKG2-D type II integral membrane protein, NKG2-D-activating NK receptor, NKG2DDNA segment on chromosome 12 (unique) 2489 expressed sequence
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.